National Institute on Drug Abuse
Director's Report to the National Advisory Council on Drug Abuse
Timothy P. Condon, Ph.D. was appointed to the positions of Associate
Director for Science Policy, NIDA, and Director of NIDA's Office of Science
Policy and Communications (OSPC). In these roles, Dr. Condon oversees the
Institute's science planning, policy, congressional and communications activities
and coordinates NIDA's research training and science education programs.
Barry Hoffer, M.D., Ph.D., a neuropharmacologist from the University
of Colorado's Health Sciences Center joined NIDA in early September as the
new Scientific Director and head of the Institute's Intramural Research
Program at the Addiction Research Center.
Harry W. Haverkos, M.D. has moved to the Intramural Research Program
at the Addiction Research Center to become more fully involved in hands-on
AIDS-related research activities.
Steven W. Gust, Ph.D. has been appointed Acting Director, Office
on AIDS (OoA).
Bennett Fletcher, Ph.D., has been selected to serve as the Acting
Chief of the Services Research Branch, DCSR.
David McCann, Ph.D., was selected as Chief of the Pharmacology and
Toxicology Branch, MDD in March 1996.
Mr. Tom Vischi of the Services Research Branch, DCSR, is on extended
detail to the Assistant Secretary for Planning and Evaluation to continue
work on managed care issues.
J.C. Comolli, R.N., M.B.A., joined the OoA in June, and Lynda Erinoff,
Ph.D. joined the office in September.
Naimah Weinberg, M.D., joined NIDA's Epidemiology Research Branch, Division
of Epidemiology and Prevention Research, in May, 1996. Most recently, Dr.
Weinberg was staff psychiatrist at Kennedy Krieger Institute in Baltimore,
and assistant professor in the division of child psychiatry at Johns Hopkins
Medical Institutions. She is a board-certified child psychiatrist, with
clinical training from the University of Michigan, and post-doctoral work
in epidemiology and public mental health at Johns Hopkins School of Hygiene
and Public Health.
Hari H. Singh, Ph.D., joined the Basic Neurobiology & Biological
Systems Research Branch, Division of Basic Research, on December 11, 1995.
Currently, he is serving as the program officer on NIDA's Drug Supply and
Analytical Services Support Program. Dr. Singh obtained his Ph.D. in chemistry
and has worked at several research institutes/universities.
Dr. Singh's expertise is in medicinal chemistry, analytical chemistry, and
biomedical sciences. Prior to coming to NIDA, he worked for the Food &
Drug Administration and the U.S. Consumer Product Safety Commission.
Jonathan D. Pollock, Ph.D., joined NIDA in July as a program officer
in the Basic Neurobiology and Biological Systems Research Branch. Dr. Pollock
was an assistant scientist at Purdue University. He did his doctoral work
in the laboratory of Eric R. Kandel at Columbia University College of Physicians
and Surgeons where he received his Ph.D. in October of 1985. He did post-doctoral
work at Caltech in the laboratory of Mark Tanouye and at the University
of Utah in the laboratory of Mario Capecchi. His expertise is in the areas
of the molecular basis of synaptic plasticity, transgenic animals, and mouse
genetics. He has published papers that have appeared in Nature Genetics,
the Journal of Biological Chemistry, and the Journal of Neuroscience as
well as commentaries that have appeared in The World and I, the magazine
of the Washington Times, and in The New York Times.
Jane Acri, Ph.D. has been selected to join the Pharmacology and Toxicology
Branch of the Medications Development Division as a Health Scientist Administrator.
Dr. Acri is currently working in the Neuroimaging/Drug Action Section of
the Division of Intramural Research. She will be concentrating her efforts
within the MDD preclinical Cocaine and Opioid Treatment Discovery Programs.
Avraham Forman, Deputy Chief of the Public Information Branch, OSPC,
retired on August 30, 1996 after 30 years with the Commissioned Corps and
17 years at NIDA.
Frank Tims, Ph.D., formerly the Chief of DCSR's Services Research Branch,
retired from Federal Service effective August 30, 1996.
Jamie Chriqui, OSPC, left NIDA in late July 1996 for a position in the
NIH Director's Award Recipients
Khursheed Asghar, Ph.D., DEPR
In recognition of his leadership, dedication, and outstanding effort
in managing the review of multiple, high priority new initiatives and a
record-breaking number of grant applications.
Helen Cesari, M.S., CRB, DEPR
In recognition of her outstanding leadership, resourcefulness, and extraordinary
contribution to the development of NIDA's extramural HIV prevention program.
Suzanne M. Cole, MASB, OPRM
In recognition of her substantial contributions in improving and enhancing
the administrative processes for the National Institute on Drug Abuse.
Timothy P. Condon, Ph.D., OSPC
In recognition of his outstanding leadership in expanding the infrastructure
for drug abuse research training and in establishing new relationships between
NIDA and the scientific community-at-large.
Jurij Mojsiak, Ph.D., MDD
In recognition of his role in the review and implementation of the NIDA
funded Medications Development Research Units at DVAMCs focused on the development
of pharmacologic treatments for cocaine dependence.
Chanvadey Nhim, MASB, OPRM
In recognition of her exemplary performance and many contributions in
support of the administrative activities of the National Institute on Drug
Commissioned Corps Outstanding Service Medal
Rebecca S. Ashery, D.S.W., PRB, DEPR
In recognition of her exceptional contributions to the field of drug
abuse in the areas of community and prevention research, AIDS education,
technology transfer, and women's issues.
Betty Tai, Ph.D., MDD
In recognition of her continuous leadership in the establishment of
a Clinical Cocaine Treatment Program.
NIDA Director Dr. Alan I. Leshner has been elected as an Honorary
Fellow of the American Psychiatric Association.
Dr. Naimah Weinberg, ERB, DEPR, was nominated to the editorial board
of the Journal of the American Academy of Child and Adolescent Psychiatry.
She has been reappointed to the Substance Abuse Committee of the American
Academy of Child and Adolescent Psychiatry.
Dr. Toni Shippenberg, DIR, received the Joseph Cochin Young Investigator
Award for outstanding research in the field of drug abuse at the annual
meeting of the College on Problems of Drug Dependence, San Juan, PR, June
Dr. Alexis Thompson, DIR, received a travel award from the International
Narcotics Research Conference to attend their annual meeting in Long Beach,
CA, July 21-26, 1996.
Over the last several months, Dr. George Uhl, DIR, served on search
committees for two NIH institutes (NIDA and NCHGR) and was appointed to
the program committee, Society for Neuroscience, and the Scientific Advisory
Board, American Parkinson's Disease Association (in recognition of his work
on monoamine transporters possibly important for neurodegeneration).
Dr. Lula Beatty, Director of NIDA's Special Populations Office, has
been appointed to the NIH Extramural Associates Advisory Board to serve
a three-year term.
Dr. Mac Horton has been appointed the 1997 Program Committee Chairperson
for the Division of the Psychology of Addictive Behaviors of the American
In June 1996, Charles O'Brien, M.D., Ph.D. of the Philadelphia
VA M.D. Program was awarded the Burlingame Award by the Institute of Living
- Hartford, CT for achievements in research and education in the area of
Dr. Nicholas Bodor, Professor of Medicinal Chemistry, Center for Drug
Discovery, University of Florida, a NIDA grantee, was awarded THE 1996 LEO
FRIEND AWARD. This award, sponsored by the I & EC Division of the American
Chemical Society (ACS), is given annually in memory of Leo Friend, the father
of CHEMTECH. Every year, one article published in CHEMTECH is chosen as
the "most significant in advancing the chemical-related sciences and/or
technology to enhance public good". Dr. Bodor is the 21st recipient
of the Leo Friend award. The manuscript written by Bodor that was selected
for the award is "Design of Biologically Safer Chemicals". Dr.
Bodor is one of the pioneers in the development of innovative methodologies
for targeted drug delivery.
of the Director][Report Index][Previous